Shanghai Laishi (002252.SZ): SR604 injection is to be included in the “Care Plan - Extension” pilot project

Zhitong Finance App News, Shanghai Laishi (002252.SZ) issued an announcement. Recently, the Drug Evaluation Center of the China Drug Administration (“CDE”) issued a notice to include the company's SR604 injection into the “Care Plan - Extension” pilot project. The publicity period ends on September 4, 2026.

According to reports, the “Care Plan - Extension” project is also known as the Rare Disease Innovative Drug Research and Development Incentive Pilot Program. The purpose of the program is to encourage the placement of innovative drugs in rare disease fields where clinical treatment is urgently needed, focus on and solve scientific problems in the development of original innovative rare disease drugs, and improve R&D efficiency. If “congenital coagulation factor VII deficiency”, one of the target indications of this SR604 injection, is officially included in the “Care Plan-Extension” pilot project at the end of the publicity period, it will receive close communication and professional guidance support from CDE in the clinical drug development process to promote attention to patients' treatment preferences and treatment experience, which is expected to promote this product to benefit patients with “congenital coagulation factor VII deficiency” earlier.